Overview

A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers

Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).
Phase:
Phase 1
Details
Lead Sponsor:
Panoptes Pharma GmbH
Treatments:
Ophthalmic Solutions